カテゴリ： GlobalData, アメリカ, 企業調査

Puretech Health plc (PRTC)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Puretech Health plc (PRTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C11480
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：80
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Puretech Health plc (Puretech), formerly PureTech Ventures LLC, is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company develops a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It also develops technology and products for screening, diagnosis, and treatment of neurological disorders such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. The company offers key experiments and de-risking programs for developing and launching new therapeutics. It markets its products across the US. Puretech is headquartered in Boston, Massachusetts, the US.

Puretech Health plc (PRTC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Puretech Health plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Puretech Health plc, Medical Devices Deals, 2012 to YTD 2018 10
Puretech Health plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Puretech Health plc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Karuna Pharma Raises USD42 Million in Series A Financing 13
resTORbio Raises USD40 Million in Series B Financing 15
resTORbio Raises USD25 Million in Series A Financing 16
Vedanta Biosciences Raises USD50 Million in Venture Financing 17
Gelesis Raises USD31.5 Million in Financing Round 18
Gelesis Raises USD12 Million in Venture Financing 19
Vedanta Biosciences Raises Funds Through Venture Financing 20
DiaTech Oncology Raises US$1.2 Million In Seed Financing 21
Partnerships 22
Akili Interactive Enters into Licensing Agreement with University of California 22
PureTech Health Enters into Co-Development Agreement with Roche 23
Entrega Enters into Agreement with Eli Lilly and Co 24
Vedanta Biosciences Enters into Agreement with Leiden University and Mitchell Cancer 25
Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 26
Vedanta Biosciences Enters into Agreement with Leiden University Medical Center 27
Vedanta Biosciences Expands Agreement with NYU Langone Medical 28
Vedanta Biosciences Enters into Agreement with NYU Langone Medical Center 29
Knode Enters Into Co-Development Agreement With AstraZeneca 30
Licensing Agreements 31
Vedanta Biosciences Enters into Licensing Agreement with JSR Corp 31
PureTech Health Enters into Licensing Agreement with 3P Biotech 32
Commense Enters into Licensing Agreement with University of British Columbia 33
PureTech Amends Licensing Agreement with Novartis 34
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 35
Vedanta Biosciences Enters into Licensing Agreement with Riken, University of Tokyo, and Azabu University 36
Equity Offering 37
Puretech Health Raises USD100 Million in Private Placement of Shares 37
resTORbio Raises USD97.8 Million in IPO of Shares 38
PureTech Health Spin Off Nybo Therapeutics 39
PureTech Raises USD195 Million in IPO 40
Debt Offering 41
Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41
Puretech Health plc – Key Competitors 42
Puretech Health plc – Key Employees 43
Puretech Health plc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 46
Financial Announcements 46
Sep 11, 2018: PureTech Health- Half-Year Report 46
Apr 16, 2018: PureTech Health Announces Annual Results for Year Ended 31 December 2017 49
Aug 30, 2017: PureTech Health: Half-Year Report For Month Ended 30 June 2017 54
Apr 06, 2017: PureTech Health Announces Annual Results for Year Ended 31 December 2016 56
Corporate Communications 60
Oct 17, 2018: PureTech’s Karuna adds Jeff Jonas, MD, to board of directors 60
Jun 05, 2018: PureTech’s Gelesis Appoints Harry Leider, former Walgreens Chief Medical Officer, as Chief Medical Officer and Paul Fonteyne, Chairman and Former CEO of Boehringer Ingelheim USA, to Board of Directors 61
May 02, 2018: PureTech Health Affiliate Sonde Adds Thai Lee to Board of Directors 62
Apr 24, 2018: PureTech Health Appoints Joep Muijrers as Chief Financial Officer 64
Apr 09, 2018: PureTech’s Commense Appoints President and Chief Executive Officer 65
Feb 20, 2018: PureTech Health: Trading Statement 66
Jan 03, 2018: PureTech Health Affiliate resTORbio Adds Lynne Sullivan, Biogen Senior Vice President, to Board of Directors 70
Jun 28, 2017: PureTech Health’s Akili Appoints Former Cubist CEO, Rob Perez, as Executive Chairman 71
Apr 13, 2017: resTORbio Appoints Joan Mannick, M.D., as Chief Medical Officer 73
Mar 02, 2017: PureTech Health Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief of Business and Strategy 74
Feb 23, 2017: PureTech Health Appoints Atul Pande M.D., Former SVP at GlaxoSmithKline, as Chief Medical Officer 75
Product News 76
Sep 17, 2018: Puretech Health collaborator publishes in nature neuroscience highlighting key role of brain lymphatics in neuroinflammatory conditions like multiple sclerosis 76
May 09, 2017: PureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of Respiratory Tract Infections 77
04/11/2017: PureTech Health Advances New Programme Targeting Immunosuppressive Gamma Delta T Cells and Related Mechanisms 78
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List of Tables
Puretech Health plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Puretech Health plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Puretech Health plc, Deals By Therapy Area, 2012 to YTD 2018 9
Puretech Health plc, Medical Devices Deals, 2012 to YTD 2018 10
Puretech Health plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karuna Pharma Raises USD42 Million in Series A Financing 13
resTORbio Raises USD40 Million in Series B Financing 15
resTORbio Raises USD25 Million in Series A Financing 16
Vedanta Biosciences Raises USD50 Million in Venture Financing 17
Gelesis Raises USD31.5 Million in Financing Round 18
Gelesis Raises USD12 Million in Venture Financing 19
Vedanta Biosciences Raises Funds Through Venture Financing 20
DiaTech Oncology Raises US$1.2 Million In Seed Financing 21
Akili Interactive Enters into Licensing Agreement with University of California 22
PureTech Health Enters into Co-Development Agreement with Roche 23
Entrega Enters into Agreement with Eli Lilly and Co 24
Vedanta Biosciences Enters into Agreement with Leiden University and Mitchell Cancer 25
Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 26
Vedanta Biosciences Enters into Agreement with Leiden University Medical Center 27
Vedanta Biosciences Expands Agreement with NYU Langone Medical 28
Vedanta Biosciences Enters into Agreement with NYU Langone Medical Center 29
Knode Enters Into Co-Development Agreement With AstraZeneca 30
Vedanta Biosciences Enters into Licensing Agreement with JSR Corp 31
PureTech Health Enters into Licensing Agreement with 3P Biotech 32
Commense Enters into Licensing Agreement with University of British Columbia 33
PureTech Amends Licensing Agreement with Novartis 34
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 35
Vedanta Biosciences Enters into Licensing Agreement with Riken, University of Tokyo, and Azabu University 36
Puretech Health Raises USD100 Million in Private Placement of Shares 37
resTORbio Raises USD97.8 Million in IPO of Shares 38
PureTech Health Spin Off Nybo Therapeutics 39
PureTech Raises USD195 Million in IPO 40
Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41
Puretech Health plc, Key Competitors 42
Puretech Health plc, Key Employees 43
Puretech Health plc, Other Locations 44
Puretech Health plc, Subsidiaries 44

List of Figures
Puretech Health plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Puretech Health plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Puretech Health plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Puretech Health plc (PRTC)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Carlisle Companies Incorporated：戦略・SWOT・企業財務分析
    Carlisle Companies Incorporated - Strategy, SWOT and Corporate Finance Report Summary Carlisle Companies Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Simulations Plus Inc (SLP)：企業の財務・戦略的SWOT分析
    Simulations Plus Inc (SLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Juniper Networks, Inc.：企業の戦略・SWOT・財務情報
    Juniper Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary Juniper Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Nativis Inc：医療機器：M&Aディール及び事業提携情報
    Summary Nativis Inc (Nativis) is a clinical stage bio-electronics company. The company provides portfolio of pipeline candidates which are under development for various therapeutic areas such as recurrent glioblastoma, brain metastisis, pain, rheumatoid arthritis, lung cancer and melanoma, among oth …
  • Bucher Industries AG：企業の戦略・SWOT・財務情報
    Bucher Industries AG - Strategy, SWOT and Corporate Finance Report Summary Bucher Industries AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tosoh Corp (4042)：企業の財務・戦略的SWOT分析
    Tosoh Corp (4042) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Wells Fargo & Company：企業の戦略・SWOT・財務情報
    Wells Fargo & Company - Strategy, SWOT and Corporate Finance Report Summary Wells Fargo & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Abbott Vascular Inc：医療機器：M&Aディール及び事業提携情報
    Summary Abbott Vascular Inc (Abbott Vascular), formerly Perclose, Inc., a subsidiary of Abbott Laboratories, is a medical device company that develops manufactures and markets cardiovascular devices. The company offers coronary intervention, peripheral intervention, and structural heart products. It …
  • Great Bear Resources Ltd (GBR)：企業の財務・戦略的SWOT分析
    Summary Great Bear Resources Ltd (GBRL) formerly Great Bear Uranium Corp, is a metals and mining company that offers minerals exploration and development services. The company acquires, mines, extracts, manages, explores, operates, produces, and develops uranium, gold, silver, base metals, and miner …
  • MS&AD Insurance Group Holdings, Inc.：企業の戦略・SWOT・財務情報
    MS&AD Insurance Group Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary MS&AD Insurance Group Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Aluar Aluminio Argentino SAIC：企業の戦略・SWOT・財務分析
    Aluar Aluminio Argentino SAIC - Strategy, SWOT and Corporate Finance Report Summary Aluar Aluminio Argentino SAIC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Canadian Tire Corp Ltd (CTC.A)：企業の財務・戦略的SWOT分析
    Canadian Tire Corp Ltd (CTC.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • General Dynamics United Kingdom Limited：企業の戦略・SWOT・財務情報
    General Dynamics United Kingdom Limited - Strategy, SWOT and Corporate Finance Report Summary General Dynamics United Kingdom Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • President Energy PLC (PPC)：企業の財務・戦略的SWOT分析
    President Energy PLC (PPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Check Point Software Technologies Ltd (CHKP)：企業の財務・戦略的SWOT分析
    Check Point Software Technologies Ltd (CHKP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Alliance MMA, Inc. (AMMA)：企業の財務・戦略的SWOT分析
    Alliance MMA, Inc. (AMMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • GeoVax Labs Inc (GOVX)：製薬・医療：M&Aディール及び事業提携情報
    Summary GeoVax Labs Inc (GeoVax) develops human vaccines for diseases caused by human immunodeficiency virus (HIV), cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company’s vaccine development programs focus on HIV, Zika virus …
  • BMC Software Inc：企業の戦略的SWOT分析
    BMC Software Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Yeda Research and Development Company Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Yeda Research and Development Company Ltd (Yeda), a subsidiary of Weizmann Institute of Science is a technology transfer company that provides research and science education. The company identifies and assesses research projects with commercial potential, protects the intellectual property o …
  • NantKwest Inc (NK)：企業の財務・戦略的SWOT分析
    Summary NantKwest Inc (NantKwest), a subsidiary of NantWorks LLC, develops natural killer (NK) cell therapies to treat cancer, infectious and inflammatory diseases by harnessing the immune system. The company is developing drugs against Merkel cell carcinoma 2L, non-small cell lung cancer 3L, multip …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆